Stocks Comparison
Maxcyte vs OmniAb: revenue, profit, margins and growth compared
Maxcyte brought in $33M of revenue in fiscal 2025, OmniAb $18.7M in fiscal 2025. Revenue changed by -14.5% at Maxcyte and -29.3% at OmniAb on the year before, so Maxcyte grew faster. Maxcyte kept -135.1% of its revenue as net profit, OmniAb -347.0%. Free cash flow was -$36.2M at Maxcyte and -$37M at OmniAb.
Side by side, latest fiscal year
| MXCT | OABI | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $33M | $18.7M |
| Revenue growth | -14.5% | -29.3% |
| Net income | -$44.6M | -$64.8M |
| Net margin | -135.1% | -347.0% |
| Free cash flow | -$36.2M | -$37M |
| Free cash flow margin | -109.5% | -198.3% |
| Earnings per share (diluted) | -$0.42 | -$0.57 |
| Cash | $20.1M | $25.5M |
| Debt | n/a | n/a |
| Price to earnings | n/a | n/a |
| Market value | $120.8M | $670.2M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #390 of 523 · Health care | #413 of 523 · Health care |
Over the years
Questions about Maxcyte and OmniAb
Which is bigger by revenue, Maxcyte or OmniAb?
Maxcyte is bigger by revenue: $33M in fiscal 2025, against $18.7M for OmniAb in fiscal 2025.
Which keeps more of its revenue as profit, Maxcyte or OmniAb?
Maxcyte had a net margin of -135.1% in fiscal 2025; OmniAb had -347.0% in fiscal 2025.
Which grew revenue faster, Maxcyte or OmniAb?
In their latest fiscal years revenue changed by -14.5% at Maxcyte and -29.3% at OmniAb.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.